img

Global Glycosylated Biosimilars Market Research Report 2024


Published on: 2024-01-04 | No of Pages : 400 | Industry : Medical

Publisher : MRA | Format : PDF

Global Glycosylated Biosimilars Market Research Report 2024

Glycosylated Biosimilars include mA, EPO etc in this report.
According to MRAResearch’s new survey, global Glycosylated Biosimilars market is projected to reach US$ million in 2033, increasing from US$ million in 2022, with the CAGR of % during the period of 2023 to 2033. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Glycosylated Biosimilars market research.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2033), aims to help readers to get a comprehensive understanding of global Glycosylated Biosimilars market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.



By Company


Sandoz
Pfizer
Teva Pahrmaceutical
Celltrion
Biocon
Amgen
Samsung Biologics
Mylan
Dr. Reddy's Laboratories
Stada Arzneimittel AG
Segment by Type
mAb
EPO

Segment by Application


Oncology
Chronic Diseases
Autoimmune Diseases
Blood Disorders
Growth Hormone Deficiency
Infectious Diseases
Other Diseases
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The Glycosylated Biosimilars report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Global market size, regional market size. Market Opportunities and Challenges
Chapter 3Companies’ Competition Patterns
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6 to 10Country Level Value Analysis
Chapter 11Companies' Outline
Chapter 12Market Conclusions
Chapter 13Research Methodology and Data Source

Table of Content

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Glycosylated Biosimilars Market Size Growth Rate by Type: 2018 VS 2022 VS 2033
1.2.2 mAb
1.2.3 EPO
1.3 Market by Application
1.3.1 Global Glycosylated Biosimilars Market Growth by Application: 2018 VS 2022 VS 2033
1.3.2 Oncology
1.3.3 Chronic Diseases
1.3.4 Autoimmune Diseases
1.3.5 Blood Disorders
1.3.6 Growth Hormone Deficiency
1.3.7 Infectious Diseases
1.3.8 Other Diseases
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Glycosylated Biosimilars Market Perspective (2018-2033)
2.2 Glycosylated Biosimilars Growth Trends by Region
2.2.1 Global Glycosylated Biosimilars Market Size by Region: 2018 VS 2022 VS 2033
2.2.2 Glycosylated Biosimilars Historic Market Size by Region (2018-2023)
2.2.3 Glycosylated Biosimilars Forecasted Market Size by Region (2024-2033)
2.3 Glycosylated Biosimilars Market Dynamics
2.3.1 Glycosylated Biosimilars Industry Trends
2.3.2 Glycosylated Biosimilars Market Drivers
2.3.3 Glycosylated Biosimilars Market Challenges
2.3.4 Glycosylated Biosimilars Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Glycosylated Biosimilars Players by Revenue
3.1.1 Global Top Glycosylated Biosimilars Players by Revenue (2018-2023)
3.1.2 Global Glycosylated Biosimilars Revenue Market Share by Players (2018-2023)
3.2 Global Glycosylated Biosimilars Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Glycosylated Biosimilars Revenue
3.4 Global Glycosylated Biosimilars Market Concentration Ratio
3.4.1 Global Glycosylated Biosimilars Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Glycosylated Biosimilars Revenue in 2022
3.5 Glycosylated Biosimilars Key Players Head office and Area Served
3.6 Key Players Glycosylated Biosimilars Product Solution and Service
3.7 Date of Enter into Glycosylated Biosimilars Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Glycosylated Biosimilars Breakdown Data by Type
4.1 Global Glycosylated Biosimilars Historic Market Size by Type (2018-2023)
4.2 Global Glycosylated Biosimilars Forecasted Market Size by Type (2024-2033)
5 Glycosylated Biosimilars Breakdown Data by Application
5.1 Global Glycosylated Biosimilars Historic Market Size by Application (2018-2023)
5.2 Global Glycosylated Biosimilars Forecasted Market Size by Application (2024-2033)
6 North America
6.1 North America Glycosylated Biosimilars Market Size (2018-2033)
6.2 North America Glycosylated Biosimilars Market Growth Rate by Country: 2018 VS 2022 VS 2033
6.3 North America Glycosylated Biosimilars Market Size by Country (2018-2023)
6.4 North America Glycosylated Biosimilars Market Size by Country (2024-2033)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Glycosylated Biosimilars Market Size (2018-2033)
7.2 Europe Glycosylated Biosimilars Market Growth Rate by Country: 2018 VS 2022 VS 2033
7.3 Europe Glycosylated Biosimilars Market Size by Country (2018-2023)
7.4 Europe Glycosylated Biosimilars Market Size by Country (2024-2033)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Glycosylated Biosimilars Market Size (2018-2033)
8.2 Asia-Pacific Glycosylated Biosimilars Market Growth Rate by Region: 2018 VS 2022 VS 2033
8.3 Asia-Pacific Glycosylated Biosimilars Market Size by Region (2018-2023)
8.4 Asia-Pacific Glycosylated Biosimilars Market Size by Region (2024-2033)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Glycosylated Biosimilars Market Size (2018-2033)
9.2 Latin America Glycosylated Biosimilars Market Growth Rate by Country: 2018 VS 2022 VS 2033
9.3 Latin America Glycosylated Biosimilars Market Size by Country (2018-2023)
9.4 Latin America Glycosylated Biosimilars Market Size by Country (2024-2033)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Glycosylated Biosimilars Market Size (2018-2033)
10.2 Middle East & Africa Glycosylated Biosimilars Market Growth Rate by Country: 2018 VS 2022 VS 2033
10.3 Middle East & Africa Glycosylated Biosimilars Market Size by Country (2018-2023)
10.4 Middle East & Africa Glycosylated Biosimilars Market Size by Country (2024-2033)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Sandoz
11.1.1 Sandoz Company Detail
11.1.2 Sandoz Business Overview
11.1.3 Sandoz Glycosylated Biosimilars Introduction
11.1.4 Sandoz Revenue in Glycosylated Biosimilars Business (2018-2023)
11.1.5 Sandoz Recent Development
11.2 Pfizer
11.2.1 Pfizer Company Detail
11.2.2 Pfizer Business Overview
11.2.3 Pfizer Glycosylated Biosimilars Introduction
11.2.4 Pfizer Revenue in Glycosylated Biosimilars Business (2018-2023)
11.2.5 Pfizer Recent Development
11.3 Teva Pahrmaceutical
11.3.1 Teva Pahrmaceutical Company Detail
11.3.2 Teva Pahrmaceutical Business Overview
11.3.3 Teva Pahrmaceutical Glycosylated Biosimilars Introduction
11.3.4 Teva Pahrmaceutical Revenue in Glycosylated Biosimilars Business (2018-2023)
11.3.5 Teva Pahrmaceutical Recent Development
11.4 Celltrion
11.4.1 Celltrion Company Detail
11.4.2 Celltrion Business Overview
11.4.3 Celltrion Glycosylated Biosimilars Introduction
11.4.4 Celltrion Revenue in Glycosylated Biosimilars Business (2018-2023)
11.4.5 Celltrion Recent Development
11.5 Biocon
11.5.1 Biocon Company Detail
11.5.2 Biocon Business Overview
11.5.3 Biocon Glycosylated Biosimilars Introduction
11.5.4 Biocon Revenue in Glycosylated Biosimilars Business (2018-2023)
11.5.5 Biocon Recent Development
11.6 Amgen
11.6.1 Amgen Company Detail
11.6.2 Amgen Business Overview
11.6.3 Amgen Glycosylated Biosimilars Introduction
11.6.4 Amgen Revenue in Glycosylated Biosimilars Business (2018-2023)
11.6.5 Amgen Recent Development
11.7 Samsung Biologics
11.7.1 Samsung Biologics Company Detail
11.7.2 Samsung Biologics Business Overview
11.7.3 Samsung Biologics Glycosylated Biosimilars Introduction
11.7.4 Samsung Biologics Revenue in Glycosylated Biosimilars Business (2018-2023)
11.7.5 Samsung Biologics Recent Development
11.8 Mylan
11.8.1 Mylan Company Detail
11.8.2 Mylan Business Overview
11.8.3 Mylan Glycosylated Biosimilars Introduction
11.8.4 Mylan Revenue in Glycosylated Biosimilars Business (2018-2023)
11.8.5 Mylan Recent Development
11.9 Dr. Reddy's Laboratories
11.9.1 Dr. Reddy's Laboratories Company Detail
11.9.2 Dr. Reddy's Laboratories Business Overview
11.9.3 Dr. Reddy's Laboratories Glycosylated Biosimilars Introduction
11.9.4 Dr. Reddy's Laboratories Revenue in Glycosylated Biosimilars Business (2018-2023)
11.9.5 Dr. Reddy's Laboratories Recent Development
11.10 Stada Arzneimittel AG
11.10.1 Stada Arzneimittel AG Company Detail
11.10.2 Stada Arzneimittel AG Business Overview
11.10.3 Stada Arzneimittel AG Glycosylated Biosimilars Introduction
11.10.4 Stada Arzneimittel AG Revenue in Glycosylated Biosimilars Business (2018-2023)
11.10.5 Stada Arzneimittel AG Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

List of Figure

List of Tables
Table 1. Global Glycosylated Biosimilars Market Size Growth Rate by Type (US$ Million): 2018 VS 2022 VS 2033
Table 2. Key Players of mAb
Table 3. Key Players of EPO
Table 4. Global Glycosylated Biosimilars Market Size Growth by Application (US$ Million): 2018 VS 2022 VS 2033
Table 5. Global Glycosylated Biosimilars Market Size by Region (US$ Million): 2018 VS 2022 VS 2033
Table 6. Global Glycosylated Biosimilars Market Size by Region (2018-2023) & (US$ Million)
Table 7. Global Glycosylated Biosimilars Market Share by Region (2018-2023)
Table 8. Global Glycosylated Biosimilars Forecasted Market Size by Region (2024-2033) & (US$ Million)
Table 9. Global Glycosylated Biosimilars Market Share by Region (2024-2033)
Table 10. Glycosylated Biosimilars Market Trends
Table 11. Glycosylated Biosimilars Market Drivers
Table 12. Glycosylated Biosimilars Market Challenges
Table 13. Glycosylated Biosimilars Market Restraints
Table 14. Global Glycosylated Biosimilars Revenue by Players (2018-2023) & (US$ Million)
Table 15. Global Glycosylated Biosimilars Market Share by Players (2018-2023)
Table 16. Global Top Glycosylated Biosimilars Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Glycosylated Biosimilars as of 2022)
Table 17. Ranking of Global Top Glycosylated Biosimilars Companies by Revenue (US$ Million) in 2022
Table 18. Global 5 Largest Players Market Share by Glycosylated Biosimilars Revenue (CR5 and HHI) & (2018-2023)
Table 19. Key Players Headquarters and Area Served
Table 20. Key Players Glycosylated Biosimilars Product Solution and Service
Table 21. Date of Enter into Glycosylated Biosimilars Market
Table 22. Mergers & Acquisitions, Expansion Plans
Table 23. Global Glycosylated Biosimilars Market Size by Type (2018-2023) & (US$ Million)
Table 24. Global Glycosylated Biosimilars Revenue Market Share by Type (2018-2023)
Table 25. Global Glycosylated Biosimilars Forecasted Market Size by Type (2024-2033) & (US$ Million)
Table 26. Global Glycosylated Biosimilars Revenue Market Share by Type (2024-2033)
Table 27. Global Glycosylated Biosimilars Market Size by Application (2018-2023) & (US$ Million)
Table 28. Global Glycosylated Biosimilars Revenue Market Share by Application (2018-2023)
Table 29. Global Glycosylated Biosimilars Forecasted Market Size by Application (2024-2033) & (US$ Million)
Table 30. Global Glycosylated Biosimilars Revenue Market Share by Application (2024-2033)
Table 31. North America Glycosylated Biosimilars Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2033
Table 32. North America Glycosylated Biosimilars Market Size by Country (2018-2023) & (US$ Million)
Table 33. North America Glycosylated Biosimilars Market Size by Country (2024-2033) & (US$ Million)
Table 34. Europe Glycosylated Biosimilars Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2033
Table 35. Europe Glycosylated Biosimilars Market Size by Country (2018-2023) & (US$ Million)
Table 36. Europe Glycosylated Biosimilars Market Size by Country (2024-2033) & (US$ Million)
Table 37. Asia-Pacific Glycosylated Biosimilars Market Size Growth Rate by Region (US$ Million): 2018 VS 2022 VS 2033
Table 38. Asia-Pacific Glycosylated Biosimilars Market Size by Region (2018-2023) & (US$ Million)
Table 39. Asia-Pacific Glycosylated Biosimilars Market Size by Region (2024-2033) & (US$ Million)
Table 40. Latin America Glycosylated Biosimilars Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2033
Table 41. Latin America Glycosylated Biosimilars Market Size by Country (2018-2023) & (US$ Million)
Table 42. Latin America Glycosylated Biosimilars Market Size by Country (2024-2033) & (US$ Million)
Table 43. Middle East & Africa Glycosylated Biosimilars Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2033
Table 44. Middle East & Africa Glycosylated Biosimilars Market Size by Country (2018-2023) & (US$ Million)
Table 45. Middle East & Africa Glycosylated Biosimilars Market Size by Country (2024-2033) & (US$ Million)
Table 46. Sandoz Company Detail
Table 47. Sandoz Business Overview
Table 48. Sandoz Glycosylated Biosimilars Product
Table 49. Sandoz Revenue in Glycosylated Biosimilars Business (2018-2023) & (US$ Million)
Table 50. Sandoz Recent Development
Table 51. Pfizer Company Detail
Table 52. Pfizer Business Overview
Table 53. Pfizer Glycosylated Biosimilars Product
Table 54. Pfizer Revenue in Glycosylated Biosimilars Business (2018-2023) & (US$ Million)
Table 55. Pfizer Recent Development
Table 56. Teva Pahrmaceutical Company Detail
Table 57. Teva Pahrmaceutical Business Overview
Table 58. Teva Pahrmaceutical Glycosylated Biosimilars Product
Table 59. Teva Pahrmaceutical Revenue in Glycosylated Biosimilars Business (2018-2023) & (US$ Million)
Table 60. Teva Pahrmaceutical Recent Development
Table 61. Celltrion Company Detail
Table 62. Celltrion Business Overview
Table 63. Celltrion Glycosylated Biosimilars Product
Table 64. Celltrion Revenue in Glycosylated Biosimilars Business (2018-2023) & (US$ Million)
Table 65. Celltrion Recent Development
Table 66. Biocon Company Detail
Table 67. Biocon Business Overview
Table 68. Biocon Glycosylated Biosimilars Product
Table 69. Biocon Revenue in Glycosylated Biosimilars Business (2018-2023) & (US$ Million)
Table 70. Biocon Recent Development
Table 71. Amgen Company Detail
Table 72. Amgen Business Overview
Table 73. Amgen Glycosylated Biosimilars Product
Table 74. Amgen Revenue in Glycosylated Biosimilars Business (2018-2023) & (US$ Million)
Table 75. Amgen Recent Development
Table 76. Samsung Biologics Company Detail
Table 77. Samsung Biologics Business Overview
Table 78. Samsung Biologics Glycosylated Biosimilars Product
Table 79. Samsung Biologics Revenue in Glycosylated Biosimilars Business (2018-2023) & (US$ Million)
Table 80. Samsung Biologics Recent Development
Table 81. Mylan Company Detail
Table 82. Mylan Business Overview
Table 83. Mylan Glycosylated Biosimilars Product
Table 84. Mylan Revenue in Glycosylated Biosimilars Business (2018-2023) & (US$ Million)
Table 85. Mylan Recent Development
Table 86. Dr. Reddy's Laboratories Company Detail
Table 87. Dr. Reddy's Laboratories Business Overview
Table 88. Dr. Reddy's Laboratories Glycosylated Biosimilars Product
Table 89. Dr. Reddy's Laboratories Revenue in Glycosylated Biosimilars Business (2018-2023) & (US$ Million)
Table 90. Dr. Reddy's Laboratories Recent Development
Table 91. Stada Arzneimittel AG Company Detail
Table 92. Stada Arzneimittel AG Business Overview
Table 93. Stada Arzneimittel AG Glycosylated Biosimilars Product
Table 94. Stada Arzneimittel AG Revenue in Glycosylated Biosimilars Business (2018-2023) & (US$ Million)
Table 95. Stada Arzneimittel AG Recent Development
Table 96. Research Programs/Design for This Report
Table 97. Key Data Information from Secondary Sources
Table 98. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Glycosylated Biosimilars Market Size Comparison by Type (2023-2033) & (US$ Million)
Figure 2. Global Glycosylated Biosimilars Market Share by Type: 2022 VS 2033
Figure 3. mAb Features
Figure 4. EPO Features
Figure 5. Global Glycosylated Biosimilars Market Size Comparison by Application (2023-2033) & (US$ Million)
Figure 6. Global Glycosylated Biosimilars Market Share by Application: 2022 VS 2033
Figure 7. Oncology Case Studies
Figure 8. Chronic Diseases Case Studies
Figure 9. Autoimmune Diseases Case Studies
Figure 10. Blood Disorders Case Studies
Figure 11. Growth Hormone Deficiency Case Studies
Figure 12. Infectious Diseases Case Studies
Figure 13. Other Diseases Case Studies
Figure 14. Glycosylated Biosimilars Report Years Considered
Figure 15. Global Glycosylated Biosimilars Market Size (US$ Million), Year-over-Year: 2018-2033
Figure 16. Global Glycosylated Biosimilars Market Size, (US$ Million), 2018 VS 2022 VS 2033
Figure 17. Global Glycosylated Biosimilars Market Share by Region: 2022 VS 2033
Figure 18. Global Glycosylated Biosimilars Market Share by Players in 2022
Figure 19. Global Top Glycosylated Biosimilars Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Glycosylated Biosimilars as of 2022)
Figure 20. The Top 10 and 5 Players Market Share by Glycosylated Biosimilars Revenue in 2022
Figure 21. North America Glycosylated Biosimilars Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 22. North America Glycosylated Biosimilars Market Share by Country (2018-2033)
Figure 23. United States Glycosylated Biosimilars Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 24. Canada Glycosylated Biosimilars Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 25. Europe Glycosylated Biosimilars Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 26. Europe Glycosylated Biosimilars Market Share by Country (2018-2033)
Figure 27. Germany Glycosylated Biosimilars Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 28. France Glycosylated Biosimilars Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 29. U.K. Glycosylated Biosimilars Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 30. Italy Glycosylated Biosimilars Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 31. Russia Glycosylated Biosimilars Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 32. Nordic Countries Glycosylated Biosimilars Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 33. Asia-Pacific Glycosylated Biosimilars Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 34. Asia-Pacific Glycosylated Biosimilars Market Share by Region (2018-2033)
Figure 35. China Glycosylated Biosimilars Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 36. Japan Glycosylated Biosimilars Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 37. South Korea Glycosylated Biosimilars Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 38. Southeast Asia Glycosylated Biosimilars Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 39. India Glycosylated Biosimilars Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 40. Australia Glycosylated Biosimilars Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 41. Latin America Glycosylated Biosimilars Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 42. Latin America Glycosylated Biosimilars Market Share by Country (2018-2033)
Figure 43. Mexico Glycosylated Biosimilars Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 44. Brazil Glycosylated Biosimilars Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 45. Middle East & Africa Glycosylated Biosimilars Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 46. Middle East & Africa Glycosylated Biosimilars Market Share by Country (2018-2033)
Figure 47. Turkey Glycosylated Biosimilars Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 48. Saudi Arabia Glycosylated Biosimilars Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 49. Sandoz Revenue Growth Rate in Glycosylated Biosimilars Business (2018-2023)
Figure 50. Pfizer Revenue Growth Rate in Glycosylated Biosimilars Business (2018-2023)
Figure 51. Teva Pahrmaceutical Revenue Growth Rate in Glycosylated Biosimilars Business (2018-2023)
Figure 52. Celltrion Revenue Growth Rate in Glycosylated Biosimilars Business (2018-2023)
Figure 53. Biocon Revenue Growth Rate in Glycosylated Biosimilars Business (2018-2023)
Figure 54. Amgen Revenue Growth Rate in Glycosylated Biosimilars Business (2018-2023)
Figure 55. Samsung Biologics Revenue Growth Rate in Glycosylated Biosimilars Business (2018-2023)
Figure 56. Mylan Revenue Growth Rate in Glycosylated Biosimilars Business (2018-2023)
Figure 57. Dr. Reddy's Laboratories Revenue Growth Rate in Glycosylated Biosimilars Business (2018-2023)
Figure 58. Stada Arzneimittel AG Revenue Growth Rate in Glycosylated Biosimilars Business (2018-2023)
Figure 59. Bottom-up and Top-down Approaches for This Report
Figure 60. Data Triangulation
Figure 61. Key Executives Interviewed